Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Yongtong TangDepartment of Pulmonary and Critical Care Medicine People's Hospital of Shangyou County Ganzhou China.
Jilan XuDepartment of Pulmonary and Critical Care Medicine People's Hospital of Shangyou County Ganzhou China.
Qingle ChenDepartment of Medical Imaging People's Hospital of Shangyou County Ganzhou China.
Jianping LuDepartment of Pulmonary and Critical Care Medicine People's Hospital of Shangyou County Ganzhou China.
Li RenDepartment of Pathology People's Hospital of Shangyou County Ganzhou China.
Taihe LanDepartment of Pulmonary and Critical Care Medicine People's Hospital of Shangyou County Ganzhou China.
Taihua LiaoDepartment of Pulmonary and Critical Care Medicine People's Hospital of Shangyou County Ganzhou China.
Xiaoling ChenGuangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou China.
Hui YiDepartment of Oncology Guangdong Provincial People's Hospital Ganzhou Hospital, Ganzhou Municipal Hospital Ganzhou China.
Jun ZhangDepartment of Pulmonary and Critical Care Medicine People's Hospital of Shangyou County Ganzhou China.
Jie HuangGuangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou China.ORCID https://orcid.org/0000-0003-2962-7950
Funding
GENE LINKAGE STUDY OF MULTIPLE SCLEROSIS SIBLING PAIRSR01NS026799 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAUSER, STEPHEN L, OKSENBERG, JORGE R. · 1989 to 2018
$6.8M
NINDS NIH HHS R01 NS026799
6 · The paper itself
Abstract
The third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is recommended universally as the standard treatment for non-small cell lung cancer (NSCLC) carrying the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Osimertinib as Salvage Therapy in Advanced Non-Small Cell Lung Cancer After Aumolertinib Resistance With T790M Mutation: A Case Report. · full record | OpenQuestion